Clostridioides difficile (formerly known as Clostridium difficile) is a gram-positive obligate anaerobe that produces exotoxins in the gastrointestinal (GI) tract resulting in watery, loose stool, abdominal pain, and nausea. The U.S. incidence of Clostridioides difficile infection (CDI) is about half a million people, with 28% community-acquired, 37% healthcare-associated, and 36% associated with long-term care facilities. Additionally, CDI has incurred one billion dollars in costs to the U.S. healthcare system. Antibiotic exposure causes changes to the GI microflora and increases the risk of developing CDI, which is especially seen in carbapenems, third-/fourth- generation cephalosporins, clindamycin, and fluoroquinolone use. Other risk factors include acid suppressive therapy; age; prolonged hospitalizations or other recent healthcare exposure; recent tube feeding or GI surgery; and immunocompromised states, including recent chemotherapy.
HCPs including: infectious diseases physicians, gastroenterologists, hospitalists, and intensivists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CDI.
This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: February 04, 2022 -- Expiration Date: February 04, 2024
Faculty: Mireya Wessolossky, MD, MPH
Faculty introduction and disclosures
· Risk factors and pathophysiology
· Clinical features and presentation
· Burden of disease
· Diagnostic tools
· NAAT, GDH assay, toxin tests
Treatment of CDI
· Treatment of CDI
o Mild to moderate CDI
o Severe CDI
o Fulminant CDI
o Recurrent CDI
· Challenges in therapy decision-making and optimal outcomes
o Overdiagnoses and delayed diagnoses
o Nonadherence to CDI guidelines
· Prevention measures
· Best practice: putting it all together
· Patient cases
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201837401ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.